Summer Street shrugs off Intercept Pharma LDL concerns

|About: Intercept Pharmaceuticals (ICPT)|By:, SA News Editor

Shares of Intercept Pharmaceuticals (ICPT -20.5%) are off their premarket lows, but are still sharply lower coming off last week's improbable run.

Count Summer Street's Bart Classen among those not too concerned with the "bad" cholesterol chatter that's at least partly responsible for today's sell-off.

Classen reportedly thinks that due to the seriousness of NASH, a potential rise in LDL likely won't be enough to deter many people from using OCA.